正在加载公司
US$2.87+1.8%11月13日 收盘
数据截至2026年6月30日，来自2026年8月17日提交的6-K
历史表现
- 1W
- +1.8%
- 1M
- -9.3%
- 3M
- -20.7%
- 6M
- -0.7%
- 1Y
- -61.3%
US$2.87+1.8%11月13日 收盘
数据截至2026年6月30日，来自2026年8月17日提交的6-K
取自公司自己的 6-K 文件。
暂无 Nasus Pharma Ltd 的业绩电话会文字记录。
“Nasus has made enormous progress in its clinical programs in the first six months of 2026, and we believe it is well positioned to advance to NS002 and NS003 toward key milestones in the second half of the year,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
Nasus Pharma Ltd. (NYSE: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Nasus Pharma Ltd 于 2026年8月17日 随业绩提交的 6-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。